

VOTE NO ON AB 2203



FACT:

Prescription Drug Prices are too High.

FACT:

AB 2203 Will Do Nothing to Lower the Price of Insulin.

FACT:

AB 2203 Will Increase Health Plan Premiums by \$20 million.

Health Plans are in full agreement that the price drug companies set for insulin is far too high. Recently reported prices for insulin by drug manufacturers show they can range from **\$275 to \$1,400 per treatment**. (OSHPD SB17 Drug Cost Increase Report September 2019)

Co-pay caps are already the law of the land in California. Lowering these limits does nothing to lower the price of insulin itself. **It is merely a Band-Aid that does nothing to heal the underlying problem: The high price Big Pharma sets for Insulin.**

Three Major Problems with AB 2203

- 1** Imposing lower co-pay limits does nothing to lower the price of the actual drug.
- 2** A co-pay limit does not limit what Big Pharma can charge purchasers for Insulin.
- 3** Gives big pharma license to set any price it wishes for insulin, ultimately driving up the cost of care by increasing premiums consumers pay by an estimated \$20 million. (CHBRP Report March 2020)


Ever-increasing prices set by Big Pharma = increased health care costs for everyone.

NO on AB 2203

VOTE NO ON AB 2203




One drug to help treat type 2 diabetes, Jardiance, **increased by over \$83 and now costs over \$1,400**. Cycloset, which also helps to treat type 2 diabetes, **increased its price by nearly \$50 to now cost over \$800**.



Source: OSHPD

NON-STOP PRICE HIKES



Source: JAMA, Business Insider, GoodRx

\$1 OUT OF EVERY \$7 SPENT ON HEALTH CARE IS USED ON DIABETES AND ITS COMPLICATIONS

Source: American Diabetes Association

PRICE INCREASES HAVE NOT SLOWED, DESPITE PROMISES FROM PHARMACEUTICAL COMPANIES.

Sources: New York Times, Axios, Good Rx

HUMALOG: SAME DRUG, NEW PRICE

The price for a standard 10 ml vial of one of the most popular insulin brands, Humalog:

Source: The Hill



A PATENTED ADVANTAGE

Unlike most drugs that have been around for decades — no generic alternatives to insulin exist. The pharmaceutical companies that control the market make small tweaks to extend the patents — gaming the system and keeping generics off the market.

Sources: New York Times, Axios, Good Rx

For more information, please go to RunawayRx.org | May 2020